The Pharma Data

JANUARY 31, 2021

It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina. The focus will be on building life science startups specializing in genomics. Participating startups must locate at the genomics incubator facility in Shanghai, China during the six-month cycle.

Life Science 52

Life Science Genome Genomics Reagent 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. When you consider the existing challenges limiting the upstream production of viral vectors, this figure becomes even more alarming. After years of safety-related setbacks and development challenges, recent progress in gene therapy is especially exciting.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Next Generation Sequencing (NGS) Library Preparation Kits. NGS Library Preparation Kits Market. Strong Intellectual Property Portfolio.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

JANUARY 24, 2021

Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. As part of his work with Juno and Kite, Dr. Bond led R&D collaborations with genome editing companies including Editas Medicine and Sangamo Therapeutics.

Engineer 52

Engineer Gene Editing Genome Genomics 52

XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Advarra

NOVEMBER 29, 2022

Dealing with confusing regulatory guidelines is one of the top obstacles researchers face as they develop CGT products 1. In the last two years, there haven’t been any CGT product approvals, primarily because of the COVID-19 pandemic. Recent Problems in Cell and Gene Therapy Development.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. 1, 2020 09:04 UTC.

Genome 52

Genome Genomics Licensing Licensing 52

Roots Analysis

AUGUST 28, 2022

The up-and-coming field of spatial genomics in biology promises to bridge the gap between high plex, high throughput, and high resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.

Genome 52

Genome Genomics RNA Genome Project 52

XTalks

OCTOBER 19, 2023

This could involve tweaking experimental conditions, changing reagents or redesigning the assay. For example, biochemical assays or medical devices are subject to certain good manufacturing practice (GMP) compliance standards, which can be industry- and product-specific.

Scientist 59

Scientist Development Research Compliance 59

pharmaphorum

FEBRUARY 3, 2021

This can be partly attributed to the reagents and delivery modalities that were available at the time of the trial start in 2016, leading to low editing efficiency at the target loci. The paradigm of patient-derived autologous CAR-T cell production hinders controllable or scalable manufacturing and on-time treatment for patients.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Pharmaceutical Technology

FEBRUARY 15, 2023

Some of the variables include the chemical composition of the LNP, the manufacturing process and of course the RNA itself, whose design and production must elicit the intended therapeutic outcome.” They can’t be derived from animal products, but they are often synthesised in low purity – 60%-70% pure. weight abundance.

Bioassay 130

Bioassay Development RNA Drugs 130

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

OCTOBER 27, 2020

.” The single-reaction panel targets five regions of the viral genome and provides excellent accuracy and sensitivity. “Most real time qPCR-based assays target only two or three targets on the viral genome.” “Most real time qPCR-based assays target only two or three targets on the viral genome.”

Genetic Analysis 52

Genetic Analysis Genome Genomics Reagent 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

MARCH 13, 2023

Before 2019, CGT drug developers still had a young, academic mindset, ordering reagents, materials, and equipment haphazardly and assuming they would show up when needed. Facilities for CGT development require a high level of maintenance, specialised equipment, and a fill/finish facility to produce sterile drug products.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Drug Discovery World

OCTOBER 12, 2022

This progress includes the expansion of genomic sciences and the ability to design cell bioprocessing platforms for biotherapeutics production that can be used to address previously unmet medical needs. However, obstacles to large-scale production and usage of these biotherapeutics are hampering progress. The glycan database .

Protein 52

Protein Gene Therapy Antibody Production 52

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. Genetic Technologies is developing a pipeline of risk assessment products.

Genetics 52

Genetics Reagent Biobanking Production 52

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. As demand for AAV gene therapies increases, it is becoming essential to maximise the efficiency and accuracy of AAV vector production. What makes an ideal AAV analytics tool for process development?

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

JUNE 6, 2023

Trends at AACR Speaking about the trends of what people are asking and are interested in on the exhibition floor, Juarez said: “I think people are just looking for quicker answers, and so that really was kind of the driving force of developing this product. A single product, quick workflow, getting you the answers as quickly as possible.

Protein 52

Protein DNA RNA Research 52

The Pharma Data

OCTOBER 14, 2020

ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. The patent is valid through 2038. Ltd of Japan. Growth Programme. Dolmatics – U.K.-based

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

Drug Discovery World

AUGUST 23, 2023

There’s even a name for the downsides of such under-supported products, poor integrations, and bad user experience: frustrated ELN users call this the “tax on science” That tax has a real cost in terms of drug discovery. ELN functionality is seamlessly integrated with electronic workflow execution.

Laboratory Information Management System 52

Laboratory Information Management System Scientist Compliance Development 52